Stereotaxis NYSEAMERICAN: STXS said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system.
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | David Leo Fischel CEO | XSTU Exchange | US85916J4094 ISIN |
| US Country | 139 Employees | - Last Dividend | 4 Nov 2013 Last Split | 12 Aug 2004 IPO Date |
Stereotaxis, Inc. is a pioneering company in the field of robotic systems, specializing in the design, manufacture, and marketing of advanced robotics, instruments, and information systems geared towards the interventional laboratory sector. Operating both in the United States and internationally, the company's cutting-edge technology primarily serves the purpose of enhancing the precision and safety of complex interventional procedures. Through its innovative solutions, Stereotaxis aims to facilitate physicians in navigating and manipulating devices within the human body with an unprecedented level of control and accuracy. Founded in 1990 and headquartered in Saint Louis, Missouri, Stereotaxis has established a strong reputation for its contribution to minimally invasive medical procedures, particularly in the realm of cardiology. The company’s commitment to innovation is also reflected in its strategic collaborations, such as with MAGiC catheter for cardiac ablation procedures, further emphasizing its role in advancing medical technology.